SSHELs are synthetic bacterial spore-like particles wherein the spore's cell surface is partially reconstituted around 1 µm-diameter silica beads coated with a lipid bilayer. Via a unique cysteine engineered in one of the surface proteins, the surface of SSHELs may be covalently decorated with molecules of interest. Here, we modified SSHELs with an affibody directed against HER2, a cell surface protein overexpressed in some breast and ovarian cancer cells, and loaded them with the chemotherapeutic agent doxorubicin.
INTRODUCTION
The efficacy of cancer chemotherapeutics can be abrogated by drug clearance and elimination, but also by delivery to non-specific sites, which can be dose-limiting. To diminish this problem, several methods employing nanometer-scale vehicles such as lipid vesicles have been devised to encase cargo for enhanced delivery to malignant cells within the tumor microenvironment [1] [2] [3] . While these strategies can improve clearance and elimination, they typically rely on passive accumulation of the vehicle near solid tumors where accumulation is due to the abnormal vasculature 4 . However, this effect can be unreliable 5 , necessitating additional strategies that actively target the delivery of cargo to specific tissue types [6] [7] [8] .
We have previously reported the assembly of synthetic bacterial spore-like particles termed "SSHELs" (Synthetic Spore Husk-Encased Lipid bilayers) 9 . Spores of Bacillus subtilis are surrounded by a protein "coat" 10 , built atop a basement layer containing two structural proteins 11 : a membrane anchor SpoVM, [12] [13] [14] [15] [16] and a cytoskeletal protein SpoIVA 17, 18 that hydrolyzes ATP to drive its static polymerization 19, 20 . We recently reconstituted these proteins around spherical lipid bilayers supported by silica beads and demonstrated that, by employing a SpoIVA engineered to contain a single reactive Cys residue, SSHELs can covalently display thousands of copies of molecules of interest 9, 21 , thereby providing a useful platform for targeted drug delivery to cell surface markers, including those on cancer cells. In many epithelial cancers, receptor tyrosine kinases (RTKs) are mutated, overexpressed, or non-functional compared to the normal phenotype 22 . One such receptor, human epidermal growth factor receptor 2 (HER2), is usually present at copy numbers that facilitate normal cell proliferation and organ development of the ovary, lung, breast, liver, kidney, and central nervous tissue 23, 24 . However, in ~25% of breast cancers it can be overexpressed, leading to aberrancies in growth and cell signaling 25 . Monoclonal antibodies targeting HER2 have been effective in some breast cancer patients 26 , but in ovarian cancers, the utility of HER2-overexpression as a prognostic factor has been unclear [27] [28] [29] [30] and clinical trials with anti-HER2 agents have been largely unsuccessful in effective treatment. One possibility is that the levels of tissue penetrance are variable such that levels needed for drug efficacy are not realized in each patient. A second is that cues from the microenvironments of human breast and ovarian tissues reduce drug efficacy. We therefore sought to designed cargo-loaded SSHELs towards HER2-positive cells using an affibody that displays high affinity towards HER2 31 . Here, we report the assembly of 1 µm-diameter SSHELs built atop mesoporous silica beads loaded with the model cargo doxorubicin, an effective FDA-approved drug that promotes DNA double strand breaks, but whose systemic administration causes side effects like hair loss, bone marrow suppression, and vomiting 32 . We demonstrate that doxorubicin-loaded SSHELs targeting HER2-positive cells effectively reduced tumor growth in a mouse tumor xenograft model of HER2-positive ovarian cancer. Growth retardation with doxorubicin-loaded SSHELs was superior to an equivalent dose of doxorubicin alone. Mechanistically, this was achieved by selective binding of particles to HER2-positive cells that were subsequently internalized and trafficked to acidified compartments, whereupon the drop in pH triggered cargo release. Finally, in a zebrafish model of breast cancer metastasis to the brain, SSHELs reduced tumor burden in this complex microenvironment. We propose that SSHELs may represent a versatile therapeutic vehicle whose targeting specificity and cargo are easily modified depending on the application.
RESULTS

Doxorubicin-encased SSHELs targeting HER2 inhibit tumor growth in a mouse xenograft model
To design biocompatible particles that can deliver cargo, we employed mesoporous silica beads containing 10 nm diameter pores and soaked them in a solution of doxorubicin ( Fig.   1A ). We chose doxorubicin as a model therapeutic agent due to its intrinsic red fluorescence that can be exploited to monitor drug loading and release kinetics, and because its pK a of 8.2 allowed facile loading into the negatively charged mesoporous beads. We then applied a phospholipid bilayer composed of phosphatidylcholine to create spherical supported lipid bilayers (SSLBs) 33 . Next, we applied synthesized SpoVM peptide to the SSLBs, after which we incubated the SpoVM-coated particles with purified SpoIVA in the presence of ATP to promote SpoIVA polymerization 11 , resulting in stable SSHEL particles. The purified SpoIVA was a variant in which a native Cys residue had been substituted, and a single unpaired Cys residue was engineered into the N-terminus 9 to allow modification with trans-cyclooctene (TCO).
As a model target cell, we chose a set of well-studied "HER2-positive" breast cancer cells. We therefore covalently attached to the surface of TCO-modified SSHELs a fluorescentlylabeled affibody that binds to HER2 with a high affinity (k d = 22 pM) that had been conjugated, via an engineered C-terminal Cys, with tetrazine, which undergoes a copper-free inverseelectron-demand Diels-Alder reaction with TCO ( Fig. 1A) 34, 35 . Fluorescence microscopy revealed that the labeled affibodies uniformly coated the SSHELs (Fig. 1B ). Quantitative flow cytometry indicated that each SSHEL particle displayed a mean of 23,500 ± 2,400 (n=3 independent labeling experiments with ~10,000 particles) molecules of equivalent soluble fluorophore (MESF) (Fig. 1C ) which, after accounting for labeling efficiency translated to each particle displaying 94,000 ± 9,600 anti-HER2 affibodies. Fluorescence microscopy of doxorubicin-loaded SSHELs (DOX-SSHEL) constructed using fluorescently labeled SpoIVA indicated that doxorubicin was successfully retained in the center of the particles after SpoIVA polymerized around the periphery of the particles (Fig. 1D ). Extraction of encased doxorubicin with detergent and measurement of its fluorescence intensity revealed that each particle contained 1.5 × 10 8 ± 1.4 × 10 7 doxorubicin molecules.
For in vivo testing, athymic nude mice were inoculated subcutaneously in the flank with SKOV3 cells, a HER2-positive ovarian cancer cell line. When the tumors reached ~100 mm 3 , mice were treated intermittently eleven times intravenously with either PBS, free doxorubicin (3 mg/kg), DOX-SSHELs displaying the αHER2 affibody (DOX-SSHEL αHER2 , using an equivalent doxorubicin dose), or empty SSHEL αHER2 . In the PBS-treated mice, the mean tumor size (n=7) reached ~1200 mm 3 in 57 days, whereas treatment with doxorubicin reduced the mean tumor size to ~800 mm 3 by day 57 (Fig. 1E , G). Treatment with SSHEL αHER2 , without drug, had a similar effect on mean tumor size as doxorubicin. However, in mice treated with DOX-SSHEL αHER2 mean tumor size was only ~300 mm 3 . At this concentration of doxorubicin, we did not observe any appreciable signs of toxicity or body weight loss ( Fig. S1A ) in any treatment group. We then repeated the experiment using 6 mg/kg of doxorubicin. In this second experiment, tumors grew slightly faster, with mean tumor size (n=7) in PBS-treated mice reaching ~1000 mm 3 in 40 days ( Fig. 1F ). Additionally, several tumors displayed ulceration (4/7) and some tumors were larger than 1500 mm 3 (2/7; Fig. 1H ). As seen in the first trial, treatment with doxorubicin or SSHEL αHER2 reduced mean tumor size to ~600 mm 3 by day 40, but several tumors from doxorubicin-treated mice were ulcerated (4/7) and one mouse experienced >10% loss in body weight. Additionally, mice in this treatment group displayed pale skin (5/7) and exhibited tissue damage at the site of injection (3/7). In mice treated with SSHEL αHER2 , we observed ulcerated tumors (3/7), and one tumor that was larger than 1500 mm 3 . In contrast, treatment with DOX-SSHEL αHER2 resulted in mean tumor size of ~300 mm 3 at day 40.
Furthermore, none of the mice displayed significant weight loss ( Fig. S1B ) and none of the tumors from this treatment displayed ulceration ( Fig. 1H ). Administration of doxorubicin via SSHEL αHER2 therefore enhanced therapeutic efficacy while reducing the adverse effects of the drug.
HER2 + cells specifically bind to and internalize SSHEL αHER2 particles
It was proposed that antibody treatment prevents shedding of the extracellular domain of HER2 and directs HER2 for internal degradation. To compare the mechanism for the increased efficacy of SSHEL-delivered drugs, we first tested the binding of fluorescently-labeled SSHEL αHER2 in vitro to two HER2 + cell lines: SKOV3 cells used in the mouse xenograft model We next incubated SKOV3 cells with AF488-labeled SSHEL αHER2 and monitored for 48 h the co-localization of particles with acidic organelles that were visualized using the fluorescent dye LysoTracker Red using confocal microscopy. Within 1 h of incubation, SSHEL αHER2 particles were located at the periphery of SKOV3 cells ( Fig. 2J ). Beginning at 4 h, SSHEL αHER2 particles began to co-localize with the LysoTracker Red dye, suggesting internalization of some of the particles and trafficking to acidic compartments. The extent of internalization increased over time, and by 48 h, the majority of cell associated SSHEL αHER2 particles colocalized with acidic compartments, consistent with the relatively slow trafficking of SSHEL αHER2 into acidic organelles.
We next tested if exposure of DOX-SSHELs to acidic pH could liberate the cargo by incubating the particles in either simulated serum (phosphate-buffered saline with 10% serum at pH 7.4) or simulated endosomal/lysosomal conditions (0.1 M citrate buffer at pH 5.0) and monitoring doxorubicin release over time. In acidic pH, encased doxorubicin was released with a half-life of 4 h, and nearly all the encased drug was released by 60 h (Fig. 2K ). In contrast, in near-neutral pH, the release of doxorubicin was reduced, with more than 50% of the drug remaining associated within the particles even after 92 h, suggesting that SSHELs are largely stable under physiological conditions, but can be disrupted or destabilized in acidic conditions, such as those found upon trafficking to an acidified compartment. unloaded SSHEL αHER2 (each at MOI= 200), or an equivalent dose of doxorubicin (120 nM). In contrast to unloaded SSHEL αHER2 , doxorubicin and DOX-SSHEL αHER2 induced caspase activity of SKBR3 cells over time (Fig. 3G) , albeit with differing kinetics (compare caspase induction at 48 h in Fig. 3G ), suggesting that the cellular uptake rates between free drugs and SSHELencapsulated drugs may differ. For SKOV3 cells, 120 nM doxorubicin did not significantly induce caspase activity, even after 72 h (Fig. 3H) , and increasing the concentration to 10 µM only resulted in an ~two-fold increase (Fig S2) , suggesting that the reduced viability of SKOV3 cells by doxorubicin shown in Fig. 3B likely resulted from a cytostatic rather than an apoptotic response 37, 38 . In contrast, treatment with DOX-SSHEL αHER2 (carrying an equivalent of just 120 nM doxorubicin) induced caspase activity in SKOV3 after 24 h.
DOX-SSHEL αHER2 particles specifically reduce viability of HER2 + cells by inducing apoptosis
DOX-SSHEL αHER2 particles enhanced HER2+ tumor clearance in a zebrafish brain metastasis model
The brain is often a site of relapsed metastatic disease for patients presenting with HER2 + breast cancers 39 . We therefore sought to directly visualize the efficacy of SSHELs in clearing small tumor lesions in a complex tumor microenvironment using a zebrafish model of brain metastasis 40 . We therefore co-injected ~200 SKBR3 cells labeled with a fluorescent dye into the hindbrains of 3 days post-fertilization (dpf) zebrafish with various treatments. In zebrafish co-injected with PBS, SKBR3 cells migrated from the site of injection 5 h after injection and greater than 60% of the injected cells could be visualized within the brain 1 day after injection ( Fig. 4A-A' ; 4E-E'; 4I). When co-injected with ~0.3 ng of doxorubicin or SSHEL αHER2 , ~60% of cells could still be detected near the site of injection 1 day after injection ( Fig. 4B-B '; 4F-F'; 4I), indicating that the efficacy of doxorubicin was much less in vivo than it was in vitro (J) Tumor clearance reported as a function of tumor size, for fish treated with PBS (black, n=15 fish), doxorubicin (blue, n=20), SSHEL αHER2 without doxorubicin (green, n=22), or doxorubicin-loaded SSHEL αHER2 (pink, n=19). Each data point represents tumor clearance in a single fish; histograms represent the aggregate of all the individual data along that axis.
DISCUSSION
The efficacy of targeting antibodies to HER2 is thought to be mediated by three possible mechanisms: 1) inhibition of HER2 extracellular domain shedding that leads to internal degradation of the receptor; 2) reducing the number of binding sites for signaling ligands; and 3) stimulation of immune-regulated antibody-dependent cellular cytotoxicity in breast cancer 23, 41 .
Trastuzumab (Herceptin) is thought function via the first mechanism, by successive degradation via ubiquitin ligase c-CBL via an unclear mechanism 42 . In contrast, SSHELs bound to HER2 on the surface were internalized by the target cells. Since HER2 is not known to mediate endocytosis 43 , we presume that the internalization occurred via a non-selective uptake mechanism such as macropinocytosis 44 or relatively slow endocytosis due to the relatively large size of the particle decorated with thousands of cell binding ligands, whereupon trafficking to an acidic compartment led to release of the SSHEL-encapsulated cargo and, in the case of a membrane-permeable drug like doxorubicin, delivery of the cargo to the cytosol. This mechanism is similar to that employed by Trastuzumab emtansine, an antibody drug conjugate (ADC) where the monoclonal antibody is covalently linked to DM1, a potent microtubule inhibitory drug that has been shown to be more potent than Trastuzumab alone 23, 45, 46 . Our findings suggest that we can merge the benefits of this adjuvant therapeutic with the efficacy of the first in line treatment options and raises the possible beneficial effects of bystander killing where membrane-permeable drug is released from a killed cell.
Our observation that uptake results in potent cytotoxicity of both ovarian and breast cancer cells suggests a more generalizable strategy for targeting other cancers that have been less successful using current antibody base strategies. Although early clinical trials with Trastuzumab did not result in reduction of tumor burden in HER2 + ovarian cancer 47, 48 , in vitro and preclinical studies suggest that the drug may sensitize tumor cells to successive treatments against EGFR. It is therefore possible that SSHELs exploit a similar mechanism wherein the anti-HER2 affibodies affixed to the surface of SSHELs "primes" the target to be more susceptible to the encapsulated doxorubicin.
Myriad strategies employing nanoparticles and even live bacteria as drug delivery vehicles have been proposed for the specific killing of cancerous cells [49] [50] [51] [52] . We suggest that SSHELs provide several unique benefits and that they may be used as an additional strategy for this purpose and may be modified easily to suit different needs. First, SSHELs are composed of defined and biologically compatible materials. Second, SSHELs may be assembled in a straightforward and stepwise manufacturing process. Third, the discovery that low pH triggers the release of SSHEL-encapsulated cargo and the observation that they are internalized by the target cell and trafficked to an acidic compartment provides a specific cue that ensures the release of cargo at the correct place and time. Furthermore, the porous silica bead can accept a wide range of molecules, including proteins and nucleic acids, to vary the type of therapeutic delivered 53 . Fourth, SSHELs exhibited low cytotoxicity, with mice tolerating multiple injections without any obvious negative response 21 . Finally, the ability to covalently link (potentially multiple 9 ) ligands at high valency to the surface of SSHELs permits the active targeting of specific cell types, instead of passive diffusion to a tumor site due to vascular leakage. This is an attractive feature as de novo resistance to antibody-based treatment is thought to occur via compensatory mechanisms mediated by activation of other RTKs. Targeted therapies at the time of diagnosis have improved survival in HER2 breast cancer, however limited options are available for patients that show relapse in the brain. One explanation for this limited efficacy is that organ-specific cues found in the brain are distinct from conditions elsewhere examined in preclinical studies. A second possibility is reduced antibody penetrance. Our results demonstrated that SSHELs alone showed potency in the zebrafish brain microenvironment for small tumors and that cargo-loaded particles were more effective in the larger tumors, thereby further highlighting the benefit of combination therapy. We therefore envision that the platform we have presented here represents a versatile and safe "microparticle" whose targeting specificity and cargo may be modified to suit a specific application.
MATERIALS AND METHODS
Cell lines and culture
Human breast cancer cell lines (SKBR3, MDA-MB-231, MCF7) and human ovarian cancer cells (SKOV3) were purchased from the American Type Culture Collection. Cells were cultured in complete growth medium, consisting of RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco) and 1X penicillin-streptomycin (Gibco). All cells were incubated at 37 °C in 5% CO 2 . 
Protein purification and labeling
SSLB preparation
Liposomes were produced by the liquid sonication method using 200 µl (25 mg/ml) of 1,2dioleoyl-sn-glycero-3-phosphocholine (DOPC, Avanti), that were first evaporated under vacuum for 3 h at room temperature and hydrated in 1 ml 0.5X PBS as described previously 33, 55 . Briefly, resuspended lipids were subjected to five freeze-thaw cycles between ethanol-dry ice bath and was removed by centrifugation at 13,000 × g for 10 min, and the supernatant containing small unilamellar vesicles was retained. One micron-diameter mesoporous silica beads (pore size of 10 nm) (Glantreo) were prepared for coating by washing three times each in 1 ml ultrapure water, followed by methanol and 1M NaOH. Beads were then rinsed and resuspended in ultrapure water (12.5 mg/ml). SSLBs were constructed by mixing 200 µl beads with 200 µl prepared liposomes at room temperature for 90 min with occasional pipetting. SSLBs were collected by centrifugation at 13,000 x g for 2 min, washed three times with 0.5X PBS and resuspended in 200 µl 0.5 X PBS.
SSHEL assembly
SSHELs were made largely as described previously 9 . Briefly, synthesized SpoVM peptide (Biomatik Corp.) was incubated at 10 μM (final concentration) with 2.5 mg/ml SSLBs in 0.5X PBS, at room temperature for 3 h with occasional pipetting. SpoVM-coated SSLBs (1 mg) were collected by centrifugation at 13,000 × g for 2 min and incubated with ~1.5 µM transcyclooctene-labeled SpoIVA in a final volume of 400 μl PBS containing 10 mM MgCl 2 and 4 mM ATP, overnight at room temperature with gentle inversion in a darkened test tube. To make SSHEL αHER2 , SSHELs were collected by centrifugation, resuspended in 400 µl PBS containing 1.5 µM methyltetrazine-labeled Ab31889, and incubated overnight at room temperature with gentle inversion. SSHEL αHER2 were collected by centrifugation, washed thrice with PBS, and stored in PBS at 4 °C. Fluorescence microscopy images of SSHELs were obtained using Delta Vision Core microscope with a Photometrics CoolSnap HQ2 camera (Applied Precision) as described previously 56 . For flow cytometry and confocal microscopy assays, 2 mg SSHELs were labeled with 10 µM of Alexa 488 Succinimidyl Ester (Life Technologies) for 1 h at room temperature prior to conjugation with affibodies. To estimate the copy number of Ab31889 conjugated onto SSHELs, the degree of labeling of Alexa 488 to Ab31889 was first estimated using absorbance measurements at 280 nm and 495 nm, and a correction factor of 0.11 for the AlexaFluor488 dye (Molecular Probes). The median fluorescence intensity (MFI) of SSHEL particles containing AlexaFluor488-labeled Ab31889 was measured using flow cytometry (FACSCanto II, BD Biosciences) and quantified using BD FACSDiva software. The MFIs were converted to molecules of equivalent soluble fluorochrome (MESF) of the SSHELs via a standard curve relating the fluorescence peaks of commercial Quantum TM AlexaFluor488 beads to their MESF values (Bangs Laboratories, Inc.); the estimated fluorophore to protein ratio (~0.25) was used for calculating the Ab31889 copy number.
Drug loading
Mesoporous silica beads (25 mg) were soaked in 200 µl doxorubicin hydrochloride (5 mM in water, Sigma) for 1 h at room temperature. Excess drug was removed via centrifugation at 13,000 × g for 1 min and discarding the supernatant. After loading, targeted SSHELs were constructed as described above. To determine the capacity of SSHELs for doxorubicin, 1 x 10 8 doxorubicin-loaded SSHEL αHER2 were incubated in 1 % SDS (dissolved in 1 ml PBS) for 24 h with inverting at 37 °C. After centrifugation (13,000 x g, 2 min), the fluorescence intensity of doxorubicin (excitation, 470 nm; emission, 585 nm) in the supernatant was measured using a fluorescence microplate reader (SPARK, Tecan) and the concentration of doxorubicin in the supernatant was calculated using a standard curve.
Cell binding assay
Cells grown in T-75 flasks (Corning) to 70-80% confluence were harvested with 10 mM EDTA in PBS for 15 min at 37 °C. Cells were washed twice with Iscove's Modified Dulbecco's Medium (IMDM, Gibco) supplemented with 10% FBS by centrifugation at 1,000 × g, for 2 min and resuspended in IMDM/FBS. Increasing ratios (multiplicities of incubation ranging from 20 to 150) of SSHEL αHER2 (labeled with AlexaFluor647) were incubated with 5 x 10 5 cells/ml in siliconized tubes (G-tubes, Bio Plas Inc.) for 1 h at 37 °C with gentle inversion. Cells were then washed with PBS once, resuspended in 1 ml PBS, and examined by flow cytometry (FACSCanto II, BD Biosciences). All data analysis was performed using FlowJo software (Tree Star). For confocal live cell imaging, 2.5 × 10 5 cells were seeded in poly-d-lysine-coated 35 mm glass-bottom dishes (MatTek) in 2 ml complete growth medium. After 24 h, cells were co-incubated with 5 x 10 7 SSHELs αHER2 labeled with AlexaFluor488 for 1 h at 37 °C. Cells were then washed twice with PBS, once with OptiMEM (Gibco), and stained with Hoechst 33342 (1 μg/ml in OptiMEM) for 30 min at 37 °C. Samples were washed three times with PBS and visualized using confocal microscopy (Zeiss LSM780). After washing once with OptiMEM, the acidic organelles of cells were stained with 300 nM LysoTracker Red DND-99 (Invitrogen) for 30 min at 37 °C. Cells were washed three times with PBS and visualized under a confocal microscope (Zeiss LSM780).
Cell viability and apoptosis assays
In vitro drug release assay
To evaluate the doxorubicin release kinetics, 1 x 10 8 doxorubicin-loaded SSHELs αHER2 were resuspended in 1 ml of physiological buffer (PBS with 10% FBS, pH 7.4) or 0.1 M citrate buffer (pH 5.0) and incubated at 37 °C with inverting. At defined time points, particles were removed via centrifugation (13,000 × g, 2 min) and fluorescence intensity of the supernatant was measured using a microplate reader. The concentration of released doxorubicin was converted into a percentage of the doxorubicin that was initially encapsulated within 10 8 particles.
Animal studies
Animal studies were conducted under protocols approved by the National Cancer Institute, and the National Institutes of Health Animal Care and Use Committee.
-Mouse experiments
Athymic nude mice (4-6 weeks old) were subcutaneously implanted with 1 x 10 7 SKOV3 cells in measurement with the formula (V = length x width 2 )/2) and expressed as mean ± standard deviation. When tumor volume reached ~100 mm 3 , mice were randomly divided into four groups (n=7 mice in each group): (1) vehicle control (PBS), (2) free doxorubivin (3 mg/kg), (3) DOX-SSHEL αHER2 , and (4) empty SSHEL αHER2 . Mice were injected via tail vein twice a week for a total of 11 injections. Tumor volumes and body weights were monitored throughout the treatment.
Statistical analysis was performed by using the nonparametric Kruskal-Wallis test, with p < 0.05 being considered significant.
-Zebrafish
We employed the transgenic line, Tg(kdrl:GFP)la116, kindly provided by Brant Weinstein (NICHD, Bethesda, MD). Zebrafish were maintained at 28.5°C on a 14-hour light/10-hour dark cycle according to standard procedures. Larvae obtained from natural spawning, raised at 28.5°C and maintained in egg water containing 0.6 g sea salt per liter of DI water were checked for normal development. At day 5 regular feeding commenced. For all experiments, at 24 hours post fertilization (hpf), larvae were transferred to egg water supplemented with phenylthiourea (PTU, Sigma P5272), suspended at 7.5% w/v in DMSO, at 1 part in 4500 to inhibit melanin formation for increased optical transparency. Larvae were then returned to the incubator at 28.5°C and checked for normal development. Zebrafish larvae at 2 days post fertilization (2 dpf) were anesthetized using 0.4% buffered tricaine. Human cells were labeled with cell tracker (Deep Red, Invitrogen) at a final concentration of 1 µM for 30 minutes as previously described 57, 58 . Cells were then centrifuged, supernatant was discarded, and the pellet was resuspended in PBS with a final cell concentration of 1 × 10 7 cells/mL before injection. 2-5 nL of labeled cells were co-injected into the hindbrain parenchyma of the larvae with PBS, 0.3 ng doxorubicin, SSHEL αHER2 without doxorubicin at MOI=200, or doxorubicin-loaded SSHEL αHER2 at MOI=200 (equivalent to 0.3 ng doxorubicin). Zebrafish were then reared at 28.5°C with 5% CO 2 and relative humidity maintained at 95% for two days. At 5 days post fertilization, some zebrafish were then returned to system water and regular feeding at 28.5 °C for long-term survival studies. Zebrafish were screened within 24 h of injection to check for successful introduction of cells.
For live cell imaging, larvae were anesthetized using 0.4% buffered tricaine, then embedded in a lateral orientation in 1% low melting point agarose (NuSieve GTG agarose, Lonza), and allowed to polymerize in with cover glass (no. 1.5 thickness) as previously described 59 . Egg water supplemented with tricaine was added to the agarose hydrogel for the entire time of data acquisition. Zebrafish were imaged on Zeiss 710 or 780 laser scanning confocal microscopes. Initial overview experiments were taken at 20×, with 1 µm Z steps, as tile scans over the entire length and height of the zebrafish. Images in the head and tail of the zebrafish were acquired at 10× magnification every 10 min for 14 h. Z stacks were acquired using a tiled approach and a 10× air objective of 0.3 NA where each individual image comprised 2046 × 2046 square pixels corresponding to 1416 × 1416 square µm for a total Z distance of 276 µm. One-photon, confocal, 2-dimensional images of 512 × 512 pixels (lateral dimensions) were acquired with a 1.4 NA 40 × oil-immersion objective. We simultaneously excited our sample with the 405 nm, 488 nm lines from an argon ion laser with a power of < 3 % (total power 30 mW) and 546 nm from a solid-state laser (power of < 10 %). A secondary dichroic mirror, SDM 560, was employed in the emission pathway to delineate the red (band-pass filters 560-575 nm) and green (band-pass filters 505-525 nm) and blue channels (480-495 nm) at a gain of 400 on the amplifier. The laser power for the 543 nm setting was set at < 3 % of the maximum power and the gain on the detectors was set to 450.
Quantification of in vivo tumor clearance-Zebrafish
Image processing was performed via ImageJ. Spectral crosstalk was removed by subtracting contributions of the red channel from the far-red detection channel. Images were then median (radius of 3 pixels) and Gaussian (sigma of 2) filtered to minimize background noise. Binary masks of cells were generated using Huang and Otsu thresholding methods on corrected images. The area occupied by cells was then calculated using ImageJ's built in 'analyze particles' function. Two-way ANOVA was used to determine statistical significance. 
